32 results about "Cns disease" patented technology

The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.

An electroencephalography (EEG) system comprises: an EEG device; a display; one or more processors; a memory; and one or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, the one or more programs including instructions for: receiving measurement data; extracting, from the measurement data, a first set of features and a second set of features; inputting the first set of features and the second set of features into a first treatment-specific machine-learning model and a second treatment-specific machine-learning model, respectively; generating a data structure based on the predicted treatment responses; and rendering, on the display, the generated data structure to provide the predicted treatment responses to the first candidate treatment of the CNS disease and the second candidate treatment of the CNS disease.

This invention describes agents, methods, compositions, kits and uses of medicaments for inhibiting or suppressing expression of TGF-β2 for treating or ameliorating the symptoms of a CNS disease in a human subject or animal, including diffuse midline glioma (DMG) and K27M GBM. The agents may be used in combination with cancer drugs. These purposes can be achieved with formulations of agents for inhibiting or suppressing expression of TGF-β2. More particularly, this invention discloses compositions, methods and uses for antisense oligonucleotides against TGF-β2, in a regimen for CNS disease. This invention further describes novel devices and methods for delivering a pharmaceutical composition by intracranial infusion.

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

The present disclosure concerns a microglia progenitor cell derived from bone marrow and / or placental stromal cells and / or umbilical cord stromal cell and methods for their isolation; as well as use of said cells for therapy of disorders of the CNS.

An electroencephalography (EEG) system comprises: an EEG device; a display; one or more processors; a memory; and one or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, the one or more programs including instructions for: receiving measurement data; extracting, from the measurement data, a first set of features and a second set of features; inputting the first set of features and the second set of features into a first treatment-specific machine-learning model and a second treatment-specific machine-learning model, respectively; generating a data structure based on the predicted treatment responses; and rendering, on the display, the generated data structure to provide the predicted treatment responses to the first candidate treatment of the CNS disease and the second candidate treatment of the CNS disease.

Aspects of the disclosure related to peripheral blocker compounds for use in reducing peripheral side effects of anti-CNS disease drugs.

The invention provides a chemical entity of Formula (I):wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Provided herein are lipid nanoparticle (LNP) compositions for use in delivering a payload to a cell in the central nervous system (CNS) of a subject. Also provided are a method for treating and / or preventing a CNS disease, kits, pharmaceutical compositions, and other compositions and methods.

Provided herein are proteins comprising a monovalent human TfR binding domain ("human TfR binding proteins"), conjugates comprising such human TfR binding proteins, e.g., human TfR binding protein-dsRNA conjugates, pharmaceutical compositions comprising human TfR binding proteins or conjugates, and methods of using human TfR binding proteins or conjugates to treat CNS diseases, e.g., neurodegenerative diseases such as neurodegenerative synucleinopathies or tauopathies.

The present invention describes the use of agents, methods, compositions, kits, and medicaments for inhibiting or suppressing the expression of TGF-β2 to treat or ameliorate symptoms of CNS diseases, including diffuse midline glioma (DMG) and K27M GBM, in human subjects or animals. The agents can be used in combination with anticancer drugs. These objectives can be achieved using formulations of agents for inhibiting or suppressing the expression of TGF-β2. More specifically, the present invention discloses compositions, methods, and uses related to antisense oligonucleotides against TGF-β2 in regimens for CNS diseases. The present invention further describes novel devices and methods for delivering pharmaceutical compositions via intracranial injection. TIFF2025538189000035.tif130133

This article describes amide prodrugs, methods for preparing such compounds, pharmaceutical compositions and medicines comprising such compounds, and methods for using such compounds in the treatment of CNS diseases or conditions.

The application relates to MSBI (Multiple Sclerosis Brain Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. These compounds are useful as early markers for the future development of cancer and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.

The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.

This invention relates to an IRAK4 degrading agent and its uses. This degrading agent can be used to treat or prevent diseases such as cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, cell death-related conditions, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases, or CNS diseases.

Described herein, inter alia, are immunophilin binding compounds and methods of heating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.

There is disclosed a compound of Formula (I):and any pharmaceutically acceptable salt or zwitterion thereof; wherein: R is hydrogen, methyl or ethyl; R1 is hydrogen or C1-C2 alkoxy; R2 is methyl or a C2-C4 group which may be saturated or unsaturated, branched or linear; and R3, R4, R5 and R6 each are independently selected from hydrogen, hydroxyl, halogen, methyl optionally substituted with hydroxy, methoxy, ethoxy, and a saturated or unsaturated C2-C3 that may be optionally substituted with hydroxyl, with the provisos that: (i) at least two of R4, R5, R6 and R7 must be hydrogen, and (ii) R3, R4, R5 and R6 may be selected such that an adjacent pair thereof join to form a ring having at least 5 members. The compound of Formula (I) is believed useful in treating a disease or disorder in a subject which may be alleviated by a 5HT2A agonist (e.g., CNS disorders and one or more symptoms of any one of depression, alcoholism, tobacco addiction, cocaine addiction, inflammation, cluster headache and PTSD in a subject).

To provide a somatostatin receptor 4 (SSTR4) modulator.SOLUTION: N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl)acetamide derivatives and pharmaceutically acceptable salts thereof are provided. The present invention also provides pharmaceutical compositions comprising N-heteroaryl-2-(heterocyclyl and heterocyclylmethyl)acetamide derivatives, and uses thereof for treating diseases, disorders, and conditions associated with SSTR4, including Alzheimer's disease and other CNS disorders. In one aspect, a compound of Formula 1 is provided.SELECTED DRAWING: None

Disclosed is a method and a brexanolone containing oral composition for treating CNS disorders such as depression. An embodiment of the invention comprises orally administering a brexanolone containing composition to a subject having a CNS disorder. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability and a predetermined ratio of bioavailability in a fed state administration relative to a fasted state administration.

To provide novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and methods of using the same.SOLUTION: Described herein are new, selective modulators of the 5-HT7 receptor. These selective compounds may be useful for the treatment of CNS and non-CNS indications. The compounds described herein may be selective in targeting 5-HT7 receptors as compared to other receptors and / or by selectively targeting 5-HT7 receptors expressed in certain tissues or organs, thereby providing effective selectivity through a particular partitioning profile of the 5-HT7 modulator.SELECTED DRAWING: None

Described herein, inter alia, are immunophilin binding compounds and methods of treating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.

The present invention provides a binding molecule which is capable of funding to the human NogoApolypeptide or human NiG with a dissociation constant < 1000nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule, an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and / or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the pefipheral (PNS) and / or centraI (CNS) nervous system.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering a 3α-OH-5α-pregnan-20-one containing composition to a subject having a CNS disorder. The composition preferably exhibits a high release rate of the 3α-OH-5α-pregnan-20-one, and when mixed with an aqueous solution, a high dispersion value. The composition is also preferably more soluble than a comparable SBE-β-CD containing composition. Further in the embodiment, the solubility of the composition when mixed in a FeSSIF is substantially similar to the solubility of the composition when mixed in a FaSSIF.

The invention relates to an IRAK4 degradation agent and application thereof. The degrading agent can be used for treating or preventing cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, diseases related to organ transplantation, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, conditions related to cell death, and the like. Thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases or CNS diseases, etc.

An electroencephalography (EEG) system comprises: an EEG device; a display; one or more processors; a memory; and one or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, the one or more programs including instructions for: receiving measurement data; extracting, from the measurement data, a first set of features and a second set of features; inputting the first set of features and the second set of features into a first treatment-specific machine-learning model and a second treatment-specific machine-learning model, respectively; generating a data structure based on the predicted treatment responses; and rendering, on the display, the generated data structure to provide the predicted treatment responses to the first candidate treatment of the CNS disease and the second candidate treatment of the CNS disease.

A system for the nasal administration of fluid drugs for CNS disease treatment. A nozzle and a base work together to deliver fluid drugs to the brain. The nozzle is generally for single use while the base is generally reusable. The purpose of such a design is to prevent contamination and minimize waste.

A chemical entity of Formula (I):wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.